Portage Biotech (NASDAQ: PRTG)
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-29 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.280 | -0.550 | -0.2700 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Portage Biotech (NASDAQ: PRTG) through any online brokerage.
Other companies in Portage Biotech’s space includes: 89bio (NASDAQ:ETNB), Adverum Biotechnologies (NASDAQ:ADVM), Inozyme Pharma (NASDAQ:INZY), Celcuity (NASDAQ:CELC) and TCR2 Therapeutics (NASDAQ:TCRR).
The latest price target for Portage Biotech (NASDAQ: PRTG) was reported by HC Wainwright & Co. on Monday, March 7, 2022. The analyst firm set a price target for 32.00 expecting PRTG to rise to within 12 months (a possible 294.57% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Portage Biotech (NASDAQ: PRTG) is $8.11 last updated Today at August 10, 2022, 8:00 PM UTC.
There are no upcoming dividends for Portage Biotech.
Portage Biotech’s Q1 earnings are confirmed for Monday, August 29, 2022.
There is no upcoming split for Portage Biotech.
Portage Biotech is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.